Literature DB >> 30130987

Survival difference between mucinous vs. non-mucinous colorectal cancer following cytoreductive surgery and intraperitoneal chemotherapy.

Yeqian Huang1, Nayef A Alzahrani1,2, Winston Liauw3, Arief Arrowaili2, David L Morris1.   

Abstract

BACKGROUND: It is believed that the oncologic behavior of mucinous colorectal adenocarcinoma (MC) is different from non-mucinous adenocarcinoma (NMC). The aim of the study is to compare long-term survivals between patients with MC and those with NMC following cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC).
METHODS: This was a retrospective study of prospectively collected data of patients with peritoneal metastases of colorectal origin following CRS and IPC. Group I included patients with MC which was defined as being composed of >50% extracellular mucin. Group II included those with NMC. Subgroup analysis was performed according to the location of primary tumor.
RESULTS: A total of 213 patients were included in this study. The two groups had similar hospital mortality, high dependency unit stay. MC group had a significantly longer mean intensive care unit (ICU) stay (p = .037) and total hospital stay (p = .037). There was no significant difference in overall survival (OS) and disease-free survival (DFS) between two groups (p = .657 and p = .938, respectively). Multivariate analysis showed that the presence of mucin was not an independent negative prognostic factor for OS (p = .190).
CONCLUSION: In summary, patients with MC had a similar long-term survival outcome with those with NMC following CRS and IPC.

Entities:  

Keywords:  HIPEC; Mucinous colorectal cancer; cytoreductive surgery; intraperitoneal chemotherapy

Mesh:

Year:  2018        PMID: 30130987     DOI: 10.1080/02656736.2018.1496486

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  2 in total

1.  Risk of relapse and death from colorectal cancer and its related factors using non-Markovian Multi-State model.

Authors:  Saeideh Hajebi Khaniki; Vahid Fakoor; Soodabeh Shahid Sales; Habibollah Esmaily; Hamid Heidarian Miri
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2020

2.  Patients with Metachronous Peritoneal Metastatic Mucinous Colorectal Adenocarcinoma Benefit More from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) than Their Synchronous Counterparts.

Authors:  Zoltan Herold; Miklos Acs; Attila Marcell Szasz; Katalin Olasz; Jana Hussong; Max Mayr; Magdolna Dank; Pompiliu Piso
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.